- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 25.11. | Biohaven muscle drug misses goal of SMA study, but advances in obesity | ||
| 22.11. | Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial | ||
| 22.11. | Lexicon to disband sales team, lay off 60% of staff | ||
| 22.11. | Will Walgreens' store closures disrupt its clinical trial aims? | ||
| 21.11. | Biotech startups are built on venture capital. Track funding rounds here. | ||
| 21.11. | Novartis wagers more than $1B on gene therapies for the nervous system | ||
| 21.11. | Amgen picks prolific biotech founder Chang as new top scientist | ||
| 21.11. | Versant startup sets out to make a new type of obesity drug | ||
| 20.11. | Sage's string of research failures continues | ||
| 20.11. | Pfizer, under pressure to change, names oncology head as new R&D chief | ||
| 20.11. | What might a Trump administration mean for the Biosecure Act? | ||
| 20.11. | Chasing new 'checkpoints,' startup Valora emerges from a Nobel winner's lab | ||
| 20.11. | Flagship, Pfizer alliance yields two more startup deals | ||
| 19.11. | Under-the-skin Keytruda comparable to infused version in Phase 3 study, Merck says | ||
| 19.11. | Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer | ||
| 19.11. | J&J pill clears skin in two late-stage psoriasis studies | ||
| 19.11. | Incyte sinks on setback for drugs acquired in $750M buyout | ||
| 18.11. | Syndax secures FDA OK for new kind of leukemia drug | ||
| 18.11. | CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest | ||
| 18.11. | FDA endorses speedy approval path for Regenxbio Duchenne gene therapy | ||
| 18.11. | Reducing variability in gene expression: bottlenecks and solutions | ||
| 18.11. | Leveraging NGS to move precision oncology forward, from CDx to commercialization | ||
| 15.11. | How a Biogen drug set the stage for a new biotech targeting ALS | ||
| 15.11. | 'Find any advantage': 3 biotech leaders on driving R&D success | ||
| 15.11. | Surviving in biotech's new normal: 5 tips from industry VCs and CEOs |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
